Vinge has advised Cinclus Pharma Holding AB (publ), a late-stage clinical pharmaceutical company developing next-generation treatments for gastric acid-related diseases listed on Nasdaq Stockholm, in connection with a long-term structured credit agreement for a total of up to EUR 28 million divided into four tranches, of which two are convertibles.
Vinge's team consisted of Dain Hård Nevonen, Louise Nässén and Hilda Andreasson (Capital Markets and Public M&A) as well as Arvid Weimers, John Andrén and Olivia Carlsten (Banking and Finance).
